Bone Density at the Hip Declines Twice as Fast in HIV-Infected Women
Femoral neck bone mineral density declines twice as fast in HIV-infected women vs HIV-infected men.
IASLC 2017
Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis
One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.
Better Diagnostics Needed for Milder HIV-Associated Neurocognitive Disorders
In order to assess and manage milder forms of HIV-associated neurocognitive disorders, effective cognitive screening instruments are needed.
Efficacy of Crofelemer in Chronic HIV-Related Diarrhea Evaluated
New findings announced from a supplemental analysis of Mytesi (crofelemer) in patients with HIV-related diarrhea.
Child Maintains HIV Remission Without ART Since 2008
A child who was diagnosed with HIV at 1 month and received early treatment has suppressed the virus without anti-HIV therapy for 8.5 years.
New WHO Guidelines for Managing Pretreatment HIV Drug Resistance
New WHO guidelines address the issue of how to manage pretreatment human immunodeficiency virus drug resistance (HIVDR) in countries where the prevalence of HIVDR is 10% or higher.
Long-Acting Injectable Antiretrovirals for HIV Effective and Safe
The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.
Dapivirine Vaginal Ring Safe and Acceptable Among Adolescent Girls
A new dapivirine vaginal ring was found to be safe and acceptable among adolescent girls in the United States.
Efficacy, Safety of Fixed-Dose HIV Regimen With Bictegravir Evaluated
Gilead announced results from 2 Phase 3 studies for the investigational fixed-dose HIV regimen with bictegravir and emtricitabine for the treatment of treatment-naive adults with HIV.
Early-Stage Trial for HIV Vaccine Shows Promise
An early stage trial for HIV vaccine regimen was able to generate immune response against HIV.
Next post in IAS 2017
